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screening for H. pylori, Hansen et al.2 reported that H. pylori
eradication resulted in a decreased ulcer incidence. Such
effect of decrease of prevalence of H. pylori and, therefore,
decrease of incidence of peptic ulcer between dialysis and
non-dialysis groups seems discrepant.1,2 We believe that
factors aside from H. pylori play an important role in the
occurrence of peptic ulcer in dialysis patients. In our 2-year
follow-up study after H. pylori eradication, we found that
peptic ulcer recurred more in dialysis patients than in non-
dialysis patients, with intention to treat analysis (8/32, 25 vs
2/64, 3.1%, P¼ 0.001, OR: 10.000, 95% CI: 1.979–50.540) or
per protocol analysis (8/29, 27.5 vs 2/64, 3.1%, P¼ 0.001,
OR: 11.429, 95% CI: 2.245–58.168).3
In addition, dialysis patients often need aspirin for
cardiovascular disease or NSAIDs for arthralgia.3,4 In
Sugimoto et al.’s study, the condition of aspirin/NSAIDs
usage is lacking; therefore, the conclusion may be misleading
when evaluating the incidence of peptic ulcer in dialysis
patients.1
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We thank Dr Tseng et al. for their useful comments and
references about the effects of Helicobacter pylori eradica-
tion therapy and the role of non-steroidal anti-inflamma-
tory drugs (NSAIDs)/aspirin in dialysis patients.1
H. pylori eradication therapy is well known to decrease
peptic ulcer incidence and recurrence in long-term
follow-up studies in both dialysis patients and patients
with normal renal function. In our study, the prevalence
of peptic ulcer in H. pylori–positive and –negative
dialysis patients was 23.3 and 12.1%, respectively; most
peptic ulcers in uninfected patients were healing to the red
scar stage, and active ulcers were rare.2 However, the
recurrence rate of peptic ulcer was reported to be much
higher in dialysis patients (25%) than in non-dialysis
patients (3%) during two years’ observation.3 These data
suggest that gastroduodenal mucosal injury in dialysis
patients occurs frequently, irrespective of H. pylori
infection.
NSAIDs/aspirin intake, systemic/local circulatory fail-
ure, hypergastrinemia, high ammonia levels, and enhanced
inflammation were considered to be the causes of mucosal
injury in H. pylori–negative dialysis patients.2 Dialysis
patients frequently receive NSAIDs/aspirin for preventing
cardiovascular diseases, and NSAIDs/aspirin should play
important roles for preventing the development of peptic
ulcer.4 In our unpublished data, most cases receiving
NSAIDs/aspirin were able to prevent active ulcer develop-
ment by acid inhibitory drugs (that is, proton pump
inhibitor and/or histamine receptor antagonist). Overall,
we recommend that both H. pylori–positive and –negative
dialysis patients receive frequent endoscopic checkups and
anti-acid drugs, especially those with a history of peptic
ulcer, hemorrhage, and use of anticoagulants and NSAIDs/
aspirin.
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Is standard GLA gene mutation
analysis definitive for the
diagnosis of Fabry disease?
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To the Editor: In their recent publication, Fervenza et al.1
outlined the relevance of a correct diagnosis of Fabry disease
for understanding an atypical phenotype in a male patient,
emphasizing that, once the correct diagnosis was suspected
during renal biopsy, they performed molecular analyses in
order to confirm the diagnosis due to the uncommon renal
presentation.
Kidney International (2009) 75, 1113–1120 1115
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We would like to draw to point out that sometimes even
the genetic diagnosis can be misleading. We have recently
reported the results of biochemical and sequence analysis
with quantification, by real-time PCR, of alternatively spliced
GLA mRNAs in five male Fabry patients.2 In this study, the
standard genomic DNA protocols based on sequencing
analysis failed to identify any mutation in a 62-year-old
male patient with a very low a-galactosidase A activity and a
classical Fabry disease phenotype. Also in his 64-year-old
sister, who suffered since youth from acroparesthesias and
abdominal pain but presented with an a-galactosidase A
activity within the normal range, the standard genomic DNA
analysis did not identify any mutation.
Because of this singular condition, studies on GLA
mRNAs on the patient’s fibroblasts using absolute real-time
RT-PCR quantification were carried out. An impressive
reduction in predominant lysosomal GLA transcripts was
detected; in contrast the alternatively spliced GLA mRNAs
were dramatically overexpressed, suggesting a transcription
regulation defect. The subsequent mRNAs sequence analysis
showed the absence of any reported mutation; genomic DNA
sequence analysis identified a new intronic mutation,
g.9273C4T, located 5 nucleotides upstream of the alternative
30 splicing junction. This genetic lesion, absent in the
normal population, was also identified in the patient’s
affected sister. These findings strongly suggest a correlation
between the new intronic mutation and the unbalanced
a-galactosidase A mRNAs ratio, which could therefore
be responsible for the reduced enzyme activity that
causes the Fabry disease. For these reasons, the recognition
of the g.9273C4T nucleotide change prompted us to
start enzyme replacement therapy (ERT) also in the affected
sister.
Our patient with the classic form of the disease and the six
patients with cardiac forms reported by Ishii et al.3 clearly
showed that alteration in synthesis or processing of the GLA
mRNAs is more frequent than expected. On the basis of such
considerations, and taking advantage of real time RT-PCR
analysis we recently developed, we argue that studies at the
transcriptome level should be included in the routine
molecular investigation when DNA standard protocols fail
to identify any genetic lesion.
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We thank Drs Mignani and Morrone for their comments
and for highlighting a role for real-time PCR in diagnosing
Fabry disease.1 However, as this method involves a skin
biopsy to obtain mRNA, we would suggest limiting this
approach to suspected Fabry patients in whom no
mutation is obtained by genomic DNA screening of the
a-galactosidase A (GALA) gene. Further, to maximize the
detection level from the genomic DNA screen it would
seem helpful to include the alternative exon and flanking
intronic regions in this analysis to identify some of the
variants highlighted by Filoni et al.2
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The importance of expert
education in enabling informed,
activated patients
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To the Editor: Finkelstein’s paper1 emphasizes ‘major
deficits’ in kidney patients’ perceived knowledge. However,
developing service-led education programs will not ensure
informed, activated patients.2 In the United Kingdom,
educational information provided by services was difficult
to understand, incomplete, and designed for the wrong
purpose.3 An awareness of the evidence from guidelines on
designing good-quality written information4 and the science
underpinning patients’ behavior and decision making is
missing from this educational information. Different types of
information structured in different ways are required for
different purposes; information to prepare patients for
vascular access surgery requires a different approach than
information enabling patients’ decisions about dialysis.
Facilitating informed, activated patients requires several
steps:5 patients need to be alerted to a decision they have
responsibility for; full information needs to be presented
without bias; patients need support to assimilate facts with
their existing values; patients need to make the decision based
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